Preparation and application of indoline-2-ketone compound derivative
High anti-lung cancer inhibitory activity was prepared by using benzophenone hydrazone with 6-methoxyisinin or 6-chloroisinininin with ketone monohydrate in the synthesis of indoline-2-one compounds. 6(E)-methoxy-3-diphenylmethyleneindoline-2-one and 6(E)-chloro-3-diphenylmethyleneindoline-2-one compounds, resolve The problem of insufficient inhibitory activity of existing compounds in anti-lung cancer cell assays was achieved, and a significant inhibitory effect was achieved.
Patent Information
- Application Number
- CN202410808698.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-21
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing indoline-2-one compounds have insufficient inhibitory activity in anti-lung cancer cell assays, especially in lung cancer A-549 cells.
6(E) was prepared by refluxing in 100 ml of chlorobenzene solvent for 48 hours, and synthesis of benzophenone hydrazone with 6-methoxyisinin or 6-chloroisinininin and ketone monohydrate by one pot method. -Methoxy-3-diphenylmethyleneindoline-2-one and 6(E)-chloro-3-diphenylmethyleneindoline-2-one compounds were then subjected to column chromatography Separation and elution gave the target crystal.
The inhibition rates of the prepared compounds in lung cancer A-549 cells reached 61.876±1.08% and 96.83±0.25%, respectively, significantly improving the anti-cancer activity.
Smart Images

Figure CN118955355A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the use of a compound, in particular to the preparation and use of an indolin-2-one, specifically to the preparation and use of a 6(E)-methoxy-3-diphenylmethylene indolin-2-one compound and a 6(E)-chloro-3-diphenylmethylene indolin-2-one compound. Background Art
[0002] Indolin-2-one compounds are important pharmaceutical intermediates with a wide range of uses. Similar synthesis methods and applications have been reported in the literature [1].
[0003] 1. References:
[0004] Synthesis and spectroscopic studies on the new Schiff base derived from the 1:1condensation of isatin with amines and its evaluating biological activity,Khubeiz,Mohamad Jawad, International Journal of ChemTech Research(2016),9(7),516-522. Summary of the invention
[0005] The compound referred to in the present invention is a compound represented by the following chemical formula (I) obtained by reacting benzophenone hydrazone, 6-methoxy isatin and acetic acid ketone monohydrate in 100 ml of chlorobenzene solvent in one pot under reflux for 48 hours:
[0006]
[0007] Its chemical name: 6(E)-methoxy-3-benzophenonehydrazone-2-indolone
[0008] Common name: Benzophenone-6-methoxyisatinazine
[0009] The compound referred to in the present invention is a compound represented by the following chemical formula (II) obtained by reacting benzophenone hydrazone, 6-chloroindigo red and acetic acid ketone monohydrate in 100 mL of anhydrous chlorobenzene solvent in a one-pot process for 60 hours:
[0010]
[0011]
[0012] Its chemical name: 6(E)-chloro-3-benzophenonehydrazone-2-indolone
[0013] Common name: Benzophenone-6-chloroindigo red azine
[0014] The synthesis method of the present compound (I) is as follows: 0.9836 g of benzophenone hydrazone, 1.000 g of 6-methoxyisatin and 0.5386 g of acetic acid ketone monohydrate are weighed and placed in a 100.0 mL flask, and 50 mL of chlorobenzene is added as a solvent. After stirring at room temperature for 48 hours, the mixture is separated by column chromatography and eluted with petroleum ether / dichloromethane (1 / 9). The last component collected is naturally evaporated to obtain 6(E)-methoxy-3-diphenylmethyleneindolin-2-one crystals.
[0015] The synthesis method of the present compound (II) is as follows: 0.9773 g of benzophenone hydrazone, 1.0041 g of 6-chloroindigo carmine and 0.6164 g of acetic acid ketone monohydrate are weighed and placed in a 100.0 mL flask, 50 mL of chlorobenzene is added as a solvent, and after stirring at room temperature for 48 hours, the mixture is separated by column chromatography and eluted with petroleum ether / dichloromethane (1 / 9), and the last component collected is naturally evaporated to obtain 6(E)-chloro-3-diphenylmethyleneindolin-2-one crystals.
[0016] The reaction mechanism of the reaction can be speculated as follows: Benzophenone hydrazone, under the action of copper salt, firstly dimerizes to form a benzophenone hydrazone dimer intermediate benzophenone azine, and then reacts with 5-methoxyisatin and 6-chloroisatin, respectively, to form the target crystalline products I and II in one step.
[0017] The target product showed certain inhibitory activity in anti-lung cancer tumor cell tests such as lung cancer A-549, and the inhibition rates were 61.876±1.08% and 96.83±0.25%, respectively. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 Single crystal diffraction pattern of benzophenone-6-methoxyisatinazine of crystalline compound (I).
[0019] Figure 2 Single crystal diffraction pattern of benzophenone-6-chloroindigoazine of crystalline compound (II). DETAILED DESCRIPTION
[0020] 1. Preparation of (6E)-methoxy-7-diphenylmethyleneindolin-2-one crystals I
[0021] In a 100mL two-necked bottle, under anhydrous and oxygen-free conditions, weigh 0.9836g of benzophenone hydrazone, 1.000g of 6-methoxyisatin and 0.5386g of acetic acid ketone monohydrate, put them into a 250mL flask, and then add 50mL of chlorobenzene as solvent. After stirring at room temperature for 48 hours, separate by column chromatography, elute with petroleum ether / dichloromethane (1 / 9), and naturally evaporate the last component collected to obtain 6(E)-methoxy-3-diphenylmethyleneindolin-2-one crystals with a yield of 42%; yellow crystals, melting point: 185-187℃; 1 HNMR(600MHz,298K,DMSO)δppm 8.3(s,1H),7.45-7.89(m,12H),7.19-7.20(m,2H),6.69-6.73(m,2H),6.22-6.27(m,1H),3.73(s,3H); 13 C{1H}NMR (150MHz, 298K, DMSO) 180.5, 167.9, 164.0, 163.3, 159.4, 154.3, 147.8, 145.7, 136.9, 134.4, 133.8, 131. 3, 130.2 (x2), 130.1, 129.4, 129.3, 129.0, 128.8, 127.3, 127.0, 111.4, 110.1, 109.5, 109.0, 97.4, 97.2, 56.7; ESI m+1 / z(%)calcd for C28H21N3O2,431.5030; found: 432.1696; ν max (cm -1 )3447,2921,1732,1612,1491,1447,1374,1240,1202,1163,1112,754,700; The crystal data of compound (I) are as follows:
[0022]
[0023] Table 1 Typical bond length data of crystals:
[0024]
[0025]
[0026]
[0027] Table 2 Typical bond angle data of crystals
[0028]
[0029]
[0030]
[0031] 2. Preparation of (6E)-chloro-7-diphenylmethyleneindolin-2-one crystal II
[0032] In a 100mL two-necked bottle, under anhydrous and oxygen-free conditions, weigh 0.9773g of benzophenone hydrazone, 1.0041g of 6-chloroindigo red and 0.6164g of acetic acid ketone monohydrate, put them into a 100.0mL flask, add 50mL of chlorobenzene as solvent, stir at room temperature for 48 hours, separate by column chromatography, elute with petroleum ether / dichloromethane (1 / 9), and naturally evaporate the last component collected to obtain 6(E)-chloro-3-diphenylmethyleneindolin-2-one crystals; yield: 45%; reddish brown crystals, melting point: 223-225℃; 1 H NMR (600MHz, 298K, DMSO) δppm 11.0 (s, 1H) 7.68-7.69 (m, 4H, ArH), 7.45-7.58 (m, 15H), 7.15-7.17 (m, 4H), 7.09-7.10 (m, 2H), 6.94-6.95 (m, 2H); 13 C{1H}NMR(150MHz,298K,DMSO)164.4,159.1,146.3,146.2,138.2,136.7,134.2,131 .4,130.3,129.4,129.1,128.9,128.8,122.9,115.9,111.4;MS(ESI)m+1 / z(%)calcd for C42H30N6O3Cl2: calcd.737.6410; found: 737.1979; ν max (cm -1 )3618,3420,3242,1741,1720,1606,1545,1531,1479,1443,1368,1322,1302,1285,1244,1209,1181,1102,1071,999,823,681,607,572,530,515; The crystal data of compound (II) are as follows:
[0033]
[0034]
[0035] Table 3. Typical bond length data of crystal (II)
[0036]
[0037]
[0038] Table 4 Typical bond angle data of crystals:
[0039]
[0040]
[0041]
[0042] 3. Anticancer activity application
[0043] The organic compound crystals I and II synthesized according to the structure design of the active natural product of the present invention both showed certain inhibitory activity in the test of anticancer cells such as lung cancer A-549, and the inhibition rates were 61.876±1.08 and 96.83±0.25 respectively. The anticancer activity test results are shown in Table 5.
[0044] Table 5 Preliminary screening results of anti-lung cancer cell activity of crystalline compounds (I) and (II)
[0045]
[0046]
Claims
1. A compound represented by the following chemical formula (I):
2. The crystal of compound (I) according to claim 1, wherein the unit cell parameters are as follows: at 273 K, on an Oxford X-ray single crystal diffractometer, using MoKα rays monochromatized by a graphite monochromator, Diffraction data are collected in an ω-θ scanning mode, characterized in that The crystal belongs to monoclinic system, I 12 / a1; unit cell parameters: α=90°; β=100.432(2)°; γ=90°.
3. A compound represented by the following chemical formula (II):
4. The crystal of compound (II) according to claim 3, wherein the unit cell parameters are as follows: at 273 K, on an Oxford X-ray single crystal diffractometer, using MoKα rays monochromatized by a graphite monochromator, Diffraction data are collected in an ω-θ scanning mode, characterized in that The crystal belongs to the triclinic system, P-1; Its unit cell parameters are: α=90°; β=114.1755(15)°; γ=90°.
5. A method for synthesizing a crystal of compound (I) according to claim 1, comprising synthesis, separation and purification. The synthesis is carried out under anhydrous and oxygen-free conditions: weigh 0.0235 g of benzophenone hydrazone, 1.0 g of 6-methoxyisatin and 0.6720 g of acetic acid ketone monohydrate complex, put them into a 250 mL flask, add 50 mL of anhydrous chlorobenzene as solvent, stir at room temperature for 60 hours, separate by column chromatography, elute with petroleum ether / dichloromethane (1 / 9), and naturally evaporate the last component collected to obtain (6E)-methoxy-7-diphenylmethyleneindolin-2-one crystals.
6. A method for synthesizing the crystal of compound (II) according to claim 2, comprising synthesis, separation and purification. The synthesis is carried out under anhydrous and oxygen-free conditions: weigh 1 g of benzophenone hydrazone, 1.0 g of 6-chloroindigo carmine and 0.6720 g of acetic acid ketone monohydrate complex, put them into a 250 mL flask, add 50 mL of chlorobenzene as solvent, stir at room temperature for 48 hours, separate by column chromatography, elute with petroleum ether / dichloromethane (1 / 9), and naturally evaporate the last component collected to obtain 6(E)-chloro-3-diphenylmethyleneindolin-2-one crystals.
7. The use of the crystalline compound (I) according to claim 1, characterized in that: The target product (I) crystal can be used as an anticancer agent and exhibits certain anticancer activity in anti-lung cancer tumor cell activity. Its IC 50 : 61.87±1.08。 8. The use of the crystalline compound (II) according to claim 2, characterized in that: The target product (II) crystal can be used as an anticancer agent and exhibits certain anticancer activity against lung cancer tumor cells. Its IC 50 :96.83±0.25.
Citation Information
Patent Citations
Preparation and application of indoline-2-ketone compound derivative
CN115304536A
Preparation and application of indoline-2-ketone compound derivative
CN116217460A
Preparation and application of indoline-2-ketone compound derivative
CN118084765A
Cited By
Preparation and application of indoline-2-ketone compound derivative
CN120923400A
